MX2023000993A - Regimen de dosis baja y formulacion de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo. - Google Patents
Regimen de dosis baja y formulacion de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo.Info
- Publication number
- MX2023000993A MX2023000993A MX2023000993A MX2023000993A MX2023000993A MX 2023000993 A MX2023000993 A MX 2023000993A MX 2023000993 A MX2023000993 A MX 2023000993A MX 2023000993 A MX2023000993 A MX 2023000993A MX 2023000993 A MX2023000993 A MX 2023000993A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- oxadiazole
- formulation
- methyl
- low dose
- Prior art date
Links
- -1 5-METHYL-1,2,4-OXADIAZOLE-3-YL COMPOUND Chemical class 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055362P | 2020-07-23 | 2020-07-23 | |
| PCT/US2021/042877 WO2022020663A1 (en) | 2020-07-23 | 2021-07-23 | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000993A true MX2023000993A (es) | 2023-03-01 |
Family
ID=77338898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000993A MX2023000993A (es) | 2020-07-23 | 2021-07-23 | Regimen de dosis baja y formulacion de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo. |
Country Status (21)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107735190B (zh) * | 2016-07-22 | 2019-11-26 | 深圳市大富科技股份有限公司 | Usb金属管件加工设备及其上模板 |
| TWI654978B (zh) * | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5-甲基-1,2,4-二唑-3-基化合物 |
| EP3829634A1 (en) * | 2018-07-31 | 2021-06-09 | Eli Lilly and Company | Combination therapy |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 EP EP21755253.8A patent/EP4185291B1/en active Active
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko not_active Withdrawn
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 ES ES21755253T patent/ES3039536T3/es active Active
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en not_active Ceased
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
- 2021-07-23 PH PH1/2023/550177A patent/PH12023550177A1/en unknown
- 2021-07-23 AU AU2021312894A patent/AU2021312894B2/en active Active
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
-
2023
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
- 2023-01-23 JO JOJO/P/2023/0018A patent/JOP20230018A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023000194A1 (es) | 2023-07-21 |
| EP4185291C0 (en) | 2025-07-09 |
| CA3186808A1 (en) | 2022-01-27 |
| AU2021312894B2 (en) | 2025-09-11 |
| PE20231031A1 (es) | 2023-07-10 |
| IL300023A (en) | 2023-03-01 |
| BR112023000975A2 (pt) | 2023-02-07 |
| KR20230043905A (ko) | 2023-03-31 |
| CN116323604A (zh) | 2023-06-23 |
| ES3039536T3 (en) | 2025-10-22 |
| ECSP23005057A (es) | 2023-02-28 |
| AR123031A1 (es) | 2022-10-26 |
| PH12023550177A1 (en) | 2024-03-18 |
| AU2021312894A1 (en) | 2023-02-23 |
| EP4185291A1 (en) | 2023-05-31 |
| US20230338349A1 (en) | 2023-10-26 |
| JOP20230018A1 (ar) | 2023-01-23 |
| DOP2023000009A (es) | 2023-02-15 |
| CO2023000594A2 (es) | 2023-01-26 |
| WO2022020663A1 (en) | 2022-01-27 |
| EP4185291B1 (en) | 2025-07-09 |
| JP2023535034A (ja) | 2023-08-15 |
| TW202220650A (zh) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240881A1 (es) | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t | |
| JOP20220267A1 (ar) | مركبات أمينو ثيازول تحمل بدائل بصفتها مثبطات لـثنائي أسيل غليسرول كيناز زيتا لتنشيط المناعة | |
| US11110104B2 (en) | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | |
| PE20210401A1 (es) | Composiciones farmaceuticas que comprenden meloxicam | |
| BRPI0508833A (pt) | formulações galênicas de compostos orgánicos | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
| JP2016532667A (ja) | ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ | |
| CO5390076A1 (es) | Composiciones farmaceuticas | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| JP2017537164A (ja) | リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ | |
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| EA202190586A1 (ru) | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 | |
| BR112015009504A2 (pt) | inibidores de rock | |
| BR112018068784A2 (pt) | método para o tratamento de leucemia | |
| US20170119760A1 (en) | Use of masitinib for the treatment of progressive supranuclear palsy | |
| MX2019003470A (es) | Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico. | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| PE20231945A1 (es) | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados | |
| PH12023550177A1 (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound. | |
| MA42769B1 (fr) | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |